In particular, it has been shown that HER2 amplification may be acquired during breast cancer progression [12], whereas in other studies, clinically relevant discrepancies in HER2 expression on CTCs and in corresponding primary tumors were reported [13,15,27]. The gene discussed is ERBB2; the disease is breast carcinoma.